Qilu is lined up to copy 2 of the blockbuster drugs on this tracker, which earned $35.5B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Qilu's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Keytruda | Merck | Biosimilar | 2028 | Stage not disclosed. US partnership signed, Sep 2026 | $31.7B |
| Invega Sustenna | Johnson & Johnson | Generic | 2031 | Filed with the FDA; court ruled for the brand Nov 2025 | $3.8B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Qilu's share of it.
Qilu has applications filed for Invega Sustenna; and a copy in development for Keytruda. It has lost in court over 1. Of the 70 makers we follow, 31 are lined up to copy more of the drugs on this tracker.
Copies with no confirmed US launch, by the earliest year each could reach the market: a settlement date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.